Key Challenges and Risk Mitigation Strategies in the Drug Repurposing Market
The Drug Repurposing Market offers promising potential but is accompanied by distinct challenges that must be addressed for sustainable growth.
One major challenge is the complexity of intellectual property (IP) rights. Since many repurposed drugs are off-patent, companies may face difficulties securing market exclusivity, which can reduce return on investment. Innovative IP strategies such as new use patents and data exclusivity are being explored to mitigate this risk.
Clinical validation poses another hurdle, as demonstrating efficacy and safety for new indications requires well-designed trials. Despite the availability of existing safety data, repurposed drugs often need indication-specific studies, which can be costly and time-consuming.
Regulatory uncertainties also complicate approval processes, with differing requirements across regions impacting global market access. Harmonization efforts are underway but remain incomplete.
Market acceptance can be slow, partly due to reimbursement challenges and physician awareness of repurposed drugs’ benefits.
To mitigate these risks, companies are adopting collaborative approaches, pooling resources, and leveraging technological tools like AI to optimize candidate selection and trial design.
Effective stakeholder engagement, regulatory dialogue, and flexible business models further enhance success rates.
Addressing these challenges proactively will be critical to unlocking the full potential of the drug repurposing market.